Afatinib (BIBW 2992), Her2/ErbB 2 and EGFR kinase inhibitor (ab142018)
Key features and details
- Potent, irreversible Her2/ErbB 2 and EGFR kinase inhibitor
- CAS Number: 850140-72-6
- Purity: > 98%
Soluble in ethanol to 25 mM and in DMSO to 100 mM
- Form / State: Powder
- Source: Synthetic
製品の概要
-
製品名
Afatinib (BIBW 2992), Her2/ErbB 2 and EGFR kinase inhibitor -
製品の詳細
Potent, irreversible Her2/ErbB 2 and EGFR kinase inhibitor -
生理活性の詳細
Potent, irreversible Her2/ErbB 2 and EGFR kinase inhibitor (IC50 values are 0.5, 0.4, 10 and 14 nM for EGFR(wt), EGFR(L858R), EGFR(L858R/T790M) and HER2 respectively). Shows antitumor effects in vivo. Orally active.
-
精製度
> 98% -
CAS 番号
850140-72-6 -
構造式
製品の特性
-
体系名
(E)-N-[4-(3-chloro-4-fluoroanilino)-7-[(3S)-oxolan-3-yl]oxyquinazolin-6-yl]-4-(dimethylamino)but-2-enamide
-
分子量
485.90 -
分子式
C24H25ClFN5O3 -
PubChem 登録番号
10184653 -
保存方法
Store at -20°C. Store under desiccating conditions. The product can be stored for up to 12 months. -
溶解性
Soluble in ethanol to 25 mM and in DMSO to 100 mM
-
使用に関する注意
Wherever possible, you should prepare and use solutions on the same day. However, if you need to make up stock solutions in advance, we recommend that you store the solution as aliquots in tightly sealed vials at -20°C. Generally, these will be useable for up to one month. Before use, and prior to opening the vial we recommend that you allow your product to equilibrate to room temperature for at least 1 hour.
Refer to SDS for further information.
Need more advice on solubility, usage and handling? Please visit our frequently asked questions (FAQ) page for more details.
-
SMILES 線形表記
CN(C)CC=CC(=O)NC1=C(C=C2C(=C1)C(=NC=N2)NC3=CC(=C(C=C3)F)Cl)OC4CCOC4 -
由来
Synthetic
-
研究分野
画像
プロトコール
To our knowledge, customised protocols are not required for this product. Please try the standard protocols listed below and let us know how you get on.
データシートおよび資料
-
SDS download
-
Datasheet download
参考文献 (1)
ab142018 は 1 報の論文で使用されています。
- Shen CH et al. ZNRF1 Mediates Epidermal Growth Factor Receptor Ubiquitination to Control Receptor Lysosomal Trafficking and Degradation. Front Cell Dev Biol 9:642625 (2021). PubMed: 33996800